[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605639":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":115,"collaborators":11,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":11,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":11,"enrollmentInfo":126,"targetDuration":11,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":143,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"RayzeBio, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation, Dose Expansion","EXPERIMENTAL",null,[13],"Drug: RYZ401",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","RYZ401","Ac-225",[9],[21],{"name":22,"affiliation":5,"role":23},"Ye Yuan, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"RayzeBio Clinical Trials","CONTACT","+1 619 657 0057","clinicaltrials@rayzebio.com",[31,45,54,63,68,77,86,95,106],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":11},"Research Facility","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-91.53017,41.66113,{"lat":43,"lon":42},{"facility":32,"status":33,"city":46,"state":47,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":11},"Lexington","Kentucky","40536",{"type":40,"coordinates":50},[51,52],-84.47772,37.98869,{"lat":52,"lon":51},{"facility":32,"status":33,"city":55,"state":56,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"St Louis","Missouri","63104",{"type":40,"coordinates":59},[60,61],-90.19789,38.62727,{"lat":61,"lon":60},{"facility":32,"status":33,"city":55,"state":56,"zip":64,"country":37,"countryCode":38,"cosmosGeoPoint":65,"geoPoint":67,"contacts":11},"63110",{"type":40,"coordinates":66},[60,61],{"lat":61,"lon":60},{"facility":32,"status":33,"city":69,"state":70,"zip":71,"country":37,"countryCode":38,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"Columbus","Ohio","43210",{"type":40,"coordinates":73},[74,75],-82.99879,39.96118,{"lat":75,"lon":74},{"facility":32,"status":33,"city":78,"state":79,"zip":80,"country":37,"countryCode":38,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"Nashville","Tennessee","37232",{"type":40,"coordinates":82},[83,84],-86.78444,36.16589,{"lat":84,"lon":83},{"facility":32,"status":33,"city":87,"state":88,"zip":89,"country":37,"countryCode":38,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"Salt Lake City","Utah","84112",{"type":40,"coordinates":91},[92,93],-111.89105,40.76078,{"lat":93,"lon":92},{"facility":32,"status":33,"city":96,"state":97,"zip":98,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Toronto","Ontario","M5G 2C4","Canada","CA",{"type":40,"coordinates":102},[103,104],-79.39864,43.70643,{"lat":104,"lon":103},{"facility":32,"status":33,"city":107,"state":108,"zip":109,"country":99,"countryCode":100,"cosmosGeoPoint":110,"geoPoint":114,"contacts":11},"Montreal","Quebec","H3T 1E2",{"type":40,"coordinates":111},[112,113],-73.58781,45.50884,{"lat":113,"lon":112},{"type":116,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605639","phase-1-study-of-ryz401-in-subjects-with-solid-tumors-expressing-sstrs-100605639",false,"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.","Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.","Inclusion criteria:\n\n* At least 18 years old at the time of signing the main study informed consent form (ICF).\n* Histologically confirmed:\n\nDose Escalation (all cohorts): Grades 1-3 WD, metastatic or locally advanced and unresectable NET at any primary site, including, but not limited to, GI, pancreatic, lung, thyroid, breast, urogenital, and adrenal tumors.\n\n* Dose Expansion Cohort A: Grades 1-3 WD, metastatic or locally advanced and unresectable GEP-NETs\n* Dose Expansion Cohort B: metastatic or locally advanced and unresectable tumors known to frequently express SSTR, limited to the following indications:\n\n  * WD NETs (Grades 1-3) from primary sites other than gastrointestinal and pancreatic (including, but not limited to, lung, thyroid, breast, urogenital, and adrenal tumors) Meningioma (Grades 1-3)\n\n    * SSTR-positive disease, as assessed by SSTR-PET imaging\n    * Adequate renal, hematologic and hepatic function\n\nExclusion criteria:\n\n* Prior RPT, including Lu-177.\n* Prior solid organ or bone marrow transplantation.\n* Use of chronic systemic steroid therapy.\n* Significant cardiovascular disease\n* Resistant hypertension\n* Uncontrolled diabetes\n* Prior history of liver cirrhosis\n* HIV, hepatitis B infection or known active hepatitis C virus infection.\n\nNote: Additional criteria may apply and will be assessed by the study site","ALL","18 Years",{"count":127,"type":128},104,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.",[134,135,136,137,138,139,140,141,142],"GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET","Solid Tumor","Somatostatin Receptor",[137,144,134,145,135,146,147,148,141,149,150,151,152,153,154,155,156,157],"SSTR+","Targeted Radiotherapy","Actinium","Ac 225","PRRT","Somatostatin Receptors","Radiopharmaceutical","BMS","Bristol Myers Squibb","Rayze","SSTR","RayzeBio","Well-differentiated NET","WD NETs","2026-06-08",{"date":160,"type":161},"2026-06-09","ACTUAL",{"date":163,"type":161},"2025-12-03",{"date":165,"type":128},"2033-04",{"name":5,"class":6},9]